SCHEMBL711980

SCHEMBL711980

O=S(=O)(Nc1nccs1)c1ccc(Nc2nc(CNCCC(c3ccccc3)c3ccccc3)cs2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 4/20 0.54
SCN5A Q14524 4/20 0.54
SCN8A Q9UQD0 4/20 0.54
SCN1B Q07699 2/20 0.54
SCN3A Q9NY46 3/20 0.52
SCN4A P35499 1/20 0.52
SCN9A Q15858 1/20 0.52
SCN2A Q99250 1/20 0.52
SCN10A Q9Y5Y9 1/20 0.52
ADRB2 P07550 1/20 0.47
ADRB1 P08588 1/20 0.47
ADRB3 P13945 1/20 0.47
EGFR P00533 1/20 0.47
KDR P35968 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 1/20 0.47
PKM P14618 2/20 0.46
CYP3A4 P08684 1/20 0.45
PTGS1 P23219 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713846 0.91 SCN1A (0.56) SCN1ASCN5ASCN8ASCN1BSCN3A
SCHEMBL711654 0.87 SCN1A (0.59) SCN1ASCN5ASCN8ASCN1BSCN3A
SCHEMBL714306 0.86 SCN1A (0.56) SCN1ASCN5ASCN8ASCN1BSCN3A
SCHEMBL713201 0.86 PKM (0.48) SCN1ASCN5ASCN8ASCN1BSCN3A
SCHEMBL714055 0.85 PKM (0.54) SCN1ASCN5ASCN8ASCN1BSCN3A
SCHEMBL713216 0.80 SCN8A (0.56) SCN1ASCN5ASCN8ASCN1BSCN3A
SCHEMBL714725 0.80 SCN8A (0.60) SCN1ASCN5ASCN8ASCN1BSCN3A
SCHEMBL3640394 0.80 ADRB2 (0.55) SCN1ASCN5ASCN8ASCN1BSCN3A
SCHEMBL710350 0.79 PKM (0.54) SCN1ASCN5ASCN8ASCN1BSCN3A
SCHEMBL714319 0.79 LMNA (0.58) SCN5ASCN3ASCN9AEGFRKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A SCN1A 2/4885SCN5A 5/4885SCN8A 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.